Country: Canada
Language: English
Source: Health Canada
PERINDOPRIL ERBUMINE
MARCAN PHARMACEUTICALS INC
C09AA04
PERINDOPRIL
8MG
TABLET
PERINDOPRIL ERBUMINE 8MG
ORAL
100/500
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0127178003; AHFS:
APPROVED
2018-04-11
_MAR-PERINDOPRIL (Perindopril Erbumine Tablets) Product Monograph_ _ _ _Page 1 of 64 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR MAR-PERINDOPRIL Perindopril Erbumine Tablets Tablets, 2 mg, 4 mg and 8 mg, Oral USP Angiotensin Converting Enzyme Inhibitor Marcan Pharmaceuticals Inc. 2 Gurdwara Road, Suite 112 Ottawa, ON K2E 1A2 Canada Date of Initial Authorization: APR 11, 2018 Date of Revision: MAY 17, 2023 Submission Control Number: 271178 _MAR-PERINDOPRIL (Perindopril Erbumine Tablets) Product Monograph_ _ _ _Page 2 of 64 _ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 05/2023 7 WARNINGS AND PRECAUTIONS 05/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................................... 2 TABLE OF CONTENTS .................................................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics (< 18 years of age) ............................................................................................................ 4 1.2 Geriatrics (>65 years of age) ............................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 5 4 DOSAGE AND ADMINISTRATION .................................................................................. 5 4.1 Dosing Considerations ........................................................................................................... Read the complete document